Search alternatives:
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
we decrease » _ decrease (Expand Search), mean decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
e fold » 5 fold (Expand Search), _ fold (Expand Search), 2 fold (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
we decrease » _ decrease (Expand Search), mean decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
e fold » 5 fold (Expand Search), _ fold (Expand Search), 2 fold (Expand Search)
-
721
-
722
-
723
-
724
-
725
-
726
Development of (2-(Benzyloxy)phenyl)methanamine Derivatives as Potent and Selective Inhibitors of CARM1 for the Treatment of Melanoma
Published 2024“…In our previous study, we have identified a series of type I PRMT inhibitors, among which ZL-28-6 (<b>6</b>) exhibited increased activity against CARM1 while displaying decreased potency against other type I PRMTs. …”
-
727
Development of (2-(Benzyloxy)phenyl)methanamine Derivatives as Potent and Selective Inhibitors of CARM1 for the Treatment of Melanoma
Published 2024“…In our previous study, we have identified a series of type I PRMT inhibitors, among which ZL-28-6 (<b>6</b>) exhibited increased activity against CARM1 while displaying decreased potency against other type I PRMTs. …”
-
728
Development of (2-(Benzyloxy)phenyl)methanamine Derivatives as Potent and Selective Inhibitors of CARM1 for the Treatment of Melanoma
Published 2024“…In our previous study, we have identified a series of type I PRMT inhibitors, among which ZL-28-6 (<b>6</b>) exhibited increased activity against CARM1 while displaying decreased potency against other type I PRMTs. …”
-
729
-
730
A Wearable Dual-Modal Patch for Rapid Pre-Hospital Diagnosis of Acute Myocardial Infarction
Published 2025“…The time required for diagnosing ischemia was significantly reduced to 50 min after its onset. The patch is optimally integrated into a stamp-sized band-aid, accompanied by a smartphone app for data visualization and real-time analysis. …”
-
731
A Wearable Dual-Modal Patch for Rapid Pre-Hospital Diagnosis of Acute Myocardial Infarction
Published 2025“…The time required for diagnosing ischemia was significantly reduced to 50 min after its onset. The patch is optimally integrated into a stamp-sized band-aid, accompanied by a smartphone app for data visualization and real-time analysis. …”
-
732
A Wearable Dual-Modal Patch for Rapid Pre-Hospital Diagnosis of Acute Myocardial Infarction
Published 2025“…The time required for diagnosing ischemia was significantly reduced to 50 min after its onset. The patch is optimally integrated into a stamp-sized band-aid, accompanied by a smartphone app for data visualization and real-time analysis. …”
-
733
First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation
Published 2022“…Low-dose <b>35m</b> remarkably decreases LPS-induced IL-1β release both <i>in vitro</i> and <i>in vivo</i> by blocking the activation of NLRP3, indicating that <b>35m</b> can be a potential orally active therapeutic agent for the treatment of NLRP3-related diseases.…”
-
734
First-in-Class Hydrazide-Based HDAC6 Selective Inhibitor with Potent Oral Anti-Inflammatory Activity by Attenuating NLRP3 Inflammasome Activation
Published 2022“…Low-dose <b>35m</b> remarkably decreases LPS-induced IL-1β release both <i>in vitro</i> and <i>in vivo</i> by blocking the activation of NLRP3, indicating that <b>35m</b> can be a potential orally active therapeutic agent for the treatment of NLRP3-related diseases.…”
-
735
-
736
-
737
-
738
Loneliness at 50+: The role of demographic and socioeconomic factors.
Published 2022“…<p>Note: The figure displays odds ratios of individual socioeconomic and demographic variables at age 50+ for three different specifications. Specification (3) includes D, a set of individual socioeconomic and demographic variables at age 50+; P, a vector of the five scores of personality traits (extraversion, agreeableness, conscientiousness, neuroticism, openness); C, a vector of childhood circumstances (wealth; health; quality of the relationship with mother, father, and friends; importance of religion), and I, country-specific fixed effects. …”
-
739
-
740